Intended use:
For in-vitro diagnostic use. RIDA®PRECISION ABCB1 is a multiplex real-time PCR for the direct qualitative detection of ABCB1 gene variants in human EDTA whole blood samples.
General information:
The ABCB1 test is a molecular genetic diagnostic procedure that assists you in treating a patient with antidepressants. The doctor can base treatment decisions on the patient’s individual genetic endowment and can select a suited antidepressant at the right dosage in short time. As a result, the patient experiences a faster onset of clinical improvement, suffers less from “trial-and-error” treatments and side effects.
Researchers at Max Planck Institute of Psychiatry in Munich have identified DNA sequence variations in the ABCB1 genetic code that influence the function of the blood brain barrier.
The ABCB1 test was developed by HMNC Brain Health and the Max Planck Institute of Psychiatry in Munich. The strongest argument for the clinical validity of the ABCB1 test is given by the meta-analysis by Breitenstein et al., 2015. The analysis comprises 16 studies with a total number of patients of n = 2037.
| Art. No. | Y5500 |
|---|---|
| Test format | real-time PCR with 50 reactions |
| Shelf life | 24 months after production |
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com/clinic.
